Skip to content

The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome

The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled, Cross Over Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01373034
Enrollment
36
Registered
2011-06-14
Start date
2011-07-31
Completion date
2012-07-31
Last updated
2011-06-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diarrhea Predominant Irritable Bowel Syndrome

Brief summary

The investigators will evaluate the efficacy of soy dietary fiber in adults with diarrhea predominant irritable bowel syndrome.

Interventions

DIETARY_SUPPLEMENTSoy Dietary Fiber

Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL

DIETARY_SUPPLEMENTRice powder

Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* willing to consent/undergo necessary procedures * between the age of 19 and 75 years * diarrhea predominant irritable bowel syndrome (satisfied with Rome II criteria)

Exclusion criteria

* uncontrolled hypertension (Blood pressure \> 170/100 mmHg) * uncontrolled diabetes mellitus (FBS \> 180 mg/dL) * malignancy, cerebrovascular disease, cardiovascular disease * history of abdominal surgery except appendectomy and hernia repair * inflammatory bowel disease * clinically or laboratory-confirmed gastroenteritis * the use of motility drug or dietary fiber supplement in 2 weeks * allergy to soy fiber * serum Cr \> 2 x Upper normal limit * AST or ALT \> 2 x Upper normal limit * Pregnancy, Lactating woman

Design outcomes

Primary

MeasureTime frameDescription
sum of irritable bowel syndrome symptom scoreafter 4 weeksabdominal pain / abdominal discomfort urgency tenesmus abdominal distension

Secondary

MeasureTime frameDescription
irritable bowel syndrome symptom scoreafter 2 weeks and 4 weeksabdominal pain / abdominal discomfort urgency tenesmus abdominal distension
Stool frequency and formafter 2 weeks and 4 weeksStool frequency (greater than 3 bowel movements/day or less than 3 bowel movements/week) Stool form (lumpy / hard or loose / watery stool)
Symptom control of irritable bowel syndromeafter 2 weeks and 4 weeks
Improvement of overall symptom in patient with irritable bowel syndromeafter 2 weeks and 4 weeks
Severity of overall symptom in patient with irritable bowel syndromeafter 2 weeks and 4 weeks
Severity of diarrheaafter 2 weeks and 4 weeks
Assessment for quality of life related with irritable bowel syndromeafter 2 weeks and 4 weeks
Assessment for patient satisfaction after administration completionafter 2 weeks and 4 weeksOverall satisfaction for treatment Whether the patient will keep up treatment

Countries

South Korea

Contacts

Primary ContactJoo Sung Kim, M.D., PhD
jooskim@snu.ac.kr+82-2-740-8112
Backup ContactKyoung Sup Hong, M.D.
kshong1@empas.com+82-10-2578-5738

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026